General Hospital Psychiatry
Volume 26, Issue 3 , Pages 233-236 , May 2004

Mood-stabilizer-maintained, remitted bipolar patients: taper and discontinuation of adjunctive antipsychotic medication

  • John R. Saksa, Psy.D.

      Affiliations

    • Department of Psychiatry, Yale University School of Medicine, 34 Park Street, New Haven, CT 06519, USA
    • Corresponding Author InformationCorresponding author. Tel.: +1-203-974-7043; fax: +1-203-974-7057.
    • ,
  • C.Bruce Baker, M.D., J.D.

      Affiliations

    • Department of Psychiatry, Yale University School of Medicine, 34 Park Street, New Haven, CT 06519, USA
    • ,
  • Scott W. Woods, M.D.

      Affiliations

    • Department of Psychiatry, Yale University School of Medicine, 34 Park Street, New Haven, CT 06519, USA

Received 24 December 2003 ,Accepted 11 February 2004.

References 

  1. Sernyak MJ, Woods SW. Chronic neuroleptic use in manic-depressive illness. Psychopharmacol Bull. 1993;29:375–381
  2. Goodwin FK, Jamison KR. Manic-depressive illness. New York: Oxford University Press; 1990;
  3. Sernyak MJ, Griffin RA, Johnson RM, et al.  Neuroleptic exposure following inpatient treatment of acute mania with lithium and neuroleptic. Am J Psychiatry. 1994;151:133–135
  4. Keck PE, Stanton SP, Tugrul KC, Bennett JA, Strakowski SM. Factors associated with maintenance antipsychotic treatment of patients with bipolar disorder. J Clin Psychiatry. 1996;57:147–151
  5. Aronson TA, Shukla S, Gujavarty K, Hoff A, DiBuono M, Khan E. Relapse in delusional depression (a retrospective study of the course of treatment). Compr Psychiatry. 1988;29:12–21
  6. Hendrick V, Altshuler LL, Szuba MP. Is there a role for neuroleptics in bipolar depression?. J Clin Psychiatry. 1994;55:533–535
  7. Russell JM, Mackell JA. Bodyweight gain associated with atypical antipsychotics (epidemiology and therapeutic implications). CNS Drugs. 2001;15:537–551
  8. Meyer JM. Novel antipsychotics and severe hyperlipidemia. J Clin Psychopharmacol. 2001;21:369–374
  9. McIntyre RS, McCann SM, Kennedy SH. Antipsychotic metabolic effects (weight gain, diabetes mellitus, and lipid abnormalities). Can J Psychiatry. 2001;46:273–281
  10. Woods SW. Olanzapine and tardive dyskinesia. [letter, comment] Br J Psychiatry. 1999;175:391–392
  11. American Psychiatric Association. Practice guideline for the treatment of patients with bipolar disorder. (revision) Am J Psychiatry. 2002;159(4 Suppl):1–50
  12. Suppes T, Webb A, Paul B, Carmody T, Kraemer H, Rush J. Clinical outcome in a randomized 1-year trial of clozapine versus treatment as usual for patients with treatment-resistant illness and a history of mania. Am J Psychiatry. 1999;156:1164–1169
  13. McElroy SL, Keck PE. Pharmacologic agents for the treatment of acute bipolar mania. Biol Psychiatry. 2000;48:539–557
  14. Tohen M, Baker RW, Altshuler LL, et al.  Olanzapine versus divalproex in the treatment of acute mania. Am J Psychiatry. 2002;159:1011–1017
  15. Baker R, Goldberg JF, Tohen M, Milton DR, Stauffer VL, Schuh LM. The impact of response to previous mood stabilizer therapy on response to olanzapine versus placebo for acute mania. Bipolar Disord. 2002;4:43–49
  16. Tohen M, Chengappa KN, Suppes T, et al.  Efficacy of olanzapine in combination with valproate or lithium in the treatment of mania in patients partially nonresponsive to valproate or lithium monotherapy. Arch Gen Psychiatry. 2002;59:62–69
  17. Vieta E, Reinares M, Corbella B, et al.  Olanzapine as long-term adjunctive therapy in treatment-resistant bipolar disorder. J Clin Psychopharmacol. 2001;21:469–473
  18. Vieta E, Gasto C, Colom F, et al.  Role of risperidone in bipolar II (an open 6-month study). J Affect Disord. 2001;67:213–219
  19. Sanger TM, Grundy SL, Gibson PJ, Namjoshi MA, Greaney MG, Tohen MF. Long-term olanzapine therapy in the treatment of bipolar I disorder (an open-label continuation phase study). J Clin Psychiatry. 2001;62:273–281
  20. Woods SW. Psychopharmacology for the clinician. [letter] J Psychiatry Neurosci. 2000;25:64

☆ This section will carry communications of work in progress, preliminary research reports, or interesting and unusual vignettes. Such reports will be considered for their practical clinical relevance or heuristic value.

PII: S0163-8343(04)00024-6

doi: 10.1016/j.genhosppsych.2004.02.002

General Hospital Psychiatry
Volume 26, Issue 3 , Pages 233-236 , May 2004

Article Tools